# Wall Street Zen

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/wall-street-zen-company
Canonical HTML page: https://getyourbrief.com/entity/wall-street-zen-company

## Timeline

- **2026-09-01**: Dividend payment — The $0.36 quarterly dividend is paid to shareholders of record as of August 17.
- **2026-08-23**: Wall Street Zen upgrades both stocks to Hold — Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
- **2026-08-22**: Wall Street Zen issues opposing ratings — Downgraded T1 Energy from Sell to Strong Sell and upgraded SM Energy from Buy to Strong Buy.
- **2026-08-17**: Ex-dividend date — Middlesex Water's quarterly dividend of $0.36 goes ex-dividend.
- **2026-08-16**: Wall Street Zen upgrades both stocks — Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold.
- **2026-08-15**: Wall Street Zen upgrades BKKT and DEI — Wall Street Zen upgraded Bakkt and Douglas Emmett from sell to hold in research notes issued Saturday morning.
- **2026-08-15**: Wall Street Zen upgrades BKKT and DEI — Wall Street Zen upgraded Bakkt and Douglas Emmett from sell to hold in research notes issued Saturday morning.
- **2026-08-14**: Quarterly earnings release — Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
- **2026-08-14**: Earnings release — Replimune Group reported ($0.72) EPS, missing the ($0.69) Zacks consensus by $0.03. Stock opened at $14.97, down $0.22.
- **2026-08-14**: Friday trading close — AMPY opened at $4.78 and BRSP opened at $5.00.
- **2026-08-14**: Enveric reports quarterly loss — Enveric Biosciences reported EPS of -$0.76 for the quarter.
- **2026-08-13**: Q2 earnings released; EPS beats consensus — Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
- **2026-08-12**: Benchmark cuts BKKT target — Benchmark reduced its Bakkt price target from $19.00 to $12.00 while maintaining a buy rating.
- **2026-08-12**: Benchmark cuts BKKT target — Benchmark reduced its Bakkt price target from $19.00 to $12.00 while maintaining a buy rating.
- **2026-08-12**: T1 Energy earnings and BTIG target move — T1 Energy reported a -$0.09 EPS loss; BTIG raised its T1 target from $8.00 to $9.00 with a Buy rating.

## Recent coverage (20 stories, network-wide)

### Hold Upgrades for CTNM and ENVB: $20.25 Target vs $1.43 Microcap
2026-08-24 11:32:31 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A Sunday analyst action shifted two healthcare microcaps from Sell to Hold. CTNM carries a $646.69M valuation and a $20.25 consensus target, while ENVB trades at $1.43 with a $6.41M market cap and negative P/E.
Full story: https://getfinancebrief.com/story/wall-street-zen-ctnm-envb-hold-upgrades-finance

### Wall Street Zen Upgrades 2 Biotechs: CTNM at $17.19, ENVB at $1.43
2026-08-24 11:32:21 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Full story: https://getbiobrief.com/story/wall-street-zen-upgrades-two-biotechs-ctnm-envb-hold-bio

### T1 Energy Cut to Strong Sell at $4.45; SM Energy Upgraded to Strong Buy
2026-08-24 03:19:53 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen issued divergent ratings on two energy names, cutting T1 Energy to Strong Sell while lifting SM Energy to Strong Buy. T1 trades at $4.45 with negative P/E and 3.5 D/E, while SM offers a 7.35 P/E and 0.85 D/E. The split highlights a rotation from leveraged loss-makers to cash-flow-positive mid-cap energy.
Full story: https://getfinancebrief.com/story/t1-energy-strong-sell-sm-energy-strong-buy-wall-street-zen-2026-08

### Applied Digital Falls 8.6% to $28.51 as Analyst Targets Split
2026-08-19 00:18:04 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Applied Digital shares slid 8.6% to $28.51 despite a Moderate Buy consensus and an average target of $68.15. The decline highlights a growing divide between sell-side optimism and trader concerns about negative earnings and elevated leverage.
Full story: https://getfinancebrief.com/story/applied-digital-8-6-percent-drop-august-2026

### Applied Digital Drops 8.6% as AI Datacenter Bets Face $8.3B Test
2026-08-19 00:17:49 · Sector: ai · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Applied Digital's 8.6% drop to $28.51, paired with a 5.1% fall in quantum peer Rigetti, signals cooling sentiment toward AI-adjacent infrastructure stocks after APLD's July earnings miss. High beta and negative EPS are forcing AI investors to reassess execution risk.
Full story: https://getaibrief.com/story/apld-8-6-percent-drop-ai-infrastructure-reckoning

### AMPY Upgraded to Hold: $4.78 Stock, $9 Target, 10.6 P/E
2026-08-18 04:52:49 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name.
Full story: https://getfinancebrief.com/story/ampy-wall-street-zen-hold-upgrade-finance

### Bakkt's $341M Market Cap Gets Hold Upgrade; Revenue Misses by 54%
2026-08-17 01:01:48 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen's sell-to-hold upgrade for Bakkt comes as the stock trades at $7.66 with a $341.53 million market cap. The move follows a 54% revenue miss and a director's $783,000 insider buy, leaving analysts divided on whether this is a bottom or a value trap.
Full story: https://getfinancebrief.com/story/bakkt-hold-upgrade-wall-street-zen-finance

### Bakkt Upgraded to Hold as BKKT Sits 85% Below Its $49.79 High
2026-08-17 01:01:34 · Sector: crypto · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Crypto platform Bakkt's sell-to-hold upgrade masks a brutal year: shares at $7.66 are down 85% from $49.79. A director's insider buy and an extreme beta of 5.91 frame the risk-reward for Web3 investors watching custody and exchange infrastructure.
Full story: https://getcryptobrief.com/story/bakkt-upgrade-hold-85-percent-below-high

### MBRX Down 97% to $0.57 Despite EPS Beat: $22 Target Stale?
2026-08-17 00:56:51 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Full story: https://getfinancebrief.com/story/mbrx-down-97-percent-eps-beat-22-target-stale

### Moleculin's $4.06M Market Cap vs ($1.40) EPS: Pipeline Survival?
2026-08-17 00:56:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Full story: https://getbiobrief.com/story/moleculin-4m-market-cap-eps-loss-pipeline-survival

### Replimune Misses EPS by $0.03; CEO Sells $510K Shares
2026-08-16 16:18:25 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Replimune missed consensus EPS by $0.03 but held near its 52-week high at $14.97. Insider sales totaling over $650,000 were tax-related, while analyst targets now range up to $17, creating a gap between the $11.86 average target and the stock price.
Full story: https://getfinancebrief.com/story/replimune-earnings-miss-stock-insiders

### Replimune's $1.26B Market Cap Faces EPS Miss as Analysts Boost Targets
2026-08-16 16:18:14 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Replimune reported ($0.72) EPS, missing by $0.03, but for biotech investors the quarter is a side note to pipeline catalysts and analyst upgrades. Insider sales were tax-related, and recent price targets of $16 to $17 suggest confidence in the oncolytic immunotherapy platform.
Full story: https://getbiobrief.com/story/replimune-earnings-miss-biotech-pipeline

### Lantern Pharma Misses EPS by $0.19; AI Oncology Stock Sits 44% Below High
2026-08-16 16:15:06 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
Full story: https://gethealthbrief.com/story/lantern-pharma-eps-miss-health-ai-oncology

### LTRN Misses EPS by $0.19 Yet Rises 0.8% to $2.65 on 2.3x Volume
2026-08-16 16:14:56 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Full story: https://getfinancebrief.com/story/ltrn-q2-earnings-miss-stock-reaction

### Lantern Pharma Posts $0.57 Loss, Misses Consensus by $0.19; Sell Rating Stands
2026-08-16 16:14:45 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Full story: https://getbiobrief.com/story/lantern-pharma-clinical-stage-eps-miss

### Safe Pro Group Misses EPS by $0.01, Yet Jumps 37.7% to $6.17
2026-08-15 00:36:38 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Safe Pro Group reported a quarterly EPS of -$0.15, one cent below consensus, but shares soared 37.7% on 21x average volume. The move pushed market cap to $128.89M even as negative net margin widened to 800.91%.
Full story: https://getfinancebrief.com/story/safe-pro-group-earnings-miss-eps-stock-surge

### Renuvion Maker Apyx Drops 1.8% to $4.38 Despite Q1 Revenue Beat
2026-08-13 02:42:20 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For healthcare and medical device stakeholders, Apyx Medical's Q1 revenue of $12.49 million beat consensus by $1.96 million, yet the stock fell 1.8% to $4.38. The decline on 60% below-average volume suggests limited conviction, while analysts maintain a moderate buy rating and $6.50 target. The company's strong liquidity ratios contrast with its negative net margin and return on equity.
Full story: https://gethealthbrief.com/story/apyx-medical-revenue-beat-stock-drop-health

### Apyx Medical EPS Beats by $0.06, Stock Still Slides 1.8% to $4.38
2026-08-13 02:42:10 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
Full story: https://getbiobrief.com/story/apyx-medical-q1-eps-beat-stock-slide-bio

### ENSC Shorts Up 619.9% at $0.30; FCUV Revenue $0.05M
2026-08-13 01:23:24 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.
Full story: https://gethealthbrief.com/story/ensc-shorts-up-619-9-fcuv-revenue-0-05m

### SCYX Short Interest Plunges 87.6% as ENSC Spikes 619.9%
2026-08-13 01:23:11 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

SCYNEXIS shorts collapsed 87.6% to 320,181 shares, signaling bear exhaustion, while Ensysce Biosciences short interest exploded 619.9% to 364,278. Focus Universal also saw a 282.8% build, reflecting a stark divergence in microcap biotech sentiment.
Full story: https://getbiobrief.com/story/scyx-short-interest-plunges-87-6-ensc-spikes-619-9

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.